The continuing challenge of lower respiratory tract infections

Clinical Infectious Diseases

Volumn 38, Issue SUPPL. 4, 2004, Pages

  Moellering Jr , Robert C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; MACROLIDE; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

AGE DISTRIBUTION; BACTERIUM ISOLATION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DNA PROBE; EDITORIAL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LEGIONELLA PNEUMOPHILA; LOWER RESPIRATORY TRACT INFECTION; MANAGEMENT; MEDICAL DOCUMENTATION; MORBIDITY; MORTALITY; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STREPTOCOCCUS MITIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 2442698837     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/382685     Document Type: Editorial

References (24)

1. Lynch JP III, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002; 34(Suppl 1):S27-46.
2. Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286:1857-62.
3. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am J Med 1985; 78(Suppl 6B):32-7.
4. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989; 11:586-99.
5. Steinhoff D, Lode H, Ruckdescel G, et al. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis 1996; 22:958-64.
6. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-80.
7. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759-76.
8. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35:556-64.
9. Wester CW, Ariga D, Nathan C, et al. Possible overestimation of penicillin resistant Streptococcus pneumoniae colonization rates due to misidentification of oropharyngeal streptococci. Diagn Microbiol Infect Dis 2002; 42:263-88.
10. Pihlajamäki M, Kotilainen P, Kaurila T, et al. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001; 33:483-8.
11. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917-24.
12. Gay K, Baughman W, Miller Y, et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis 2000; 182:1417-24.
13. Garcia-Rey C, Aguilar L, Baquero F, et al. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 2002; 40:159-64.
14. Farrell DJ, Morrissey I, Bakker S, et al. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002; 50(Suppl S1):39-47.
15. Gruneberg RN. Global surveillance through PROTEKT: the first year. J Chemother 2002; 14(Suppl 3):9-16.
16. Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998; 27:764-70.
17. Sahm DF, Karlowsky JA, Kelly LJ, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 2001; 45:1037-42.
18. Thornsberry C, Jones ME, Hickey ML, et al. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother 1999; 44:749-59.
19. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002; 34(Suppl 1):S4-16.
20. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45:191-203.
21. Song JH, Lee NY, Ichiyama S, et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin Infect Dis 1999; 28:1206-11.
22. Nagai K, Appelbaum PC, Davies TA, et al. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and Eastern European countries. Antimicrob Agents Chemother 2002; 46:371-7.
23. Ronchetti MP, Guglielmi F, Latini L, et al. Resistance patterns of Streptococcus pneumoniae from children in central Italy. Eur J Clin Microbiol Infect Dis 1999; 18:376-9.
24. Corso A, Severina EP, Petruk VF, et al. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 1998; 4:325-37.